BridgeBio Pharma, Inc. Quarterly Debt-to-equity in % from Q2 2020 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
BridgeBio Pharma, Inc. quarterly Debt-to-equity history and growth rate from Q2 2020 to Q3 2024.
  • BridgeBio Pharma, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -159 %, a 8.65% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -159 -12.7 -8.65% Sep 30, 2024
Q2 2024 -159 -10.5 -7.03% Jun 30, 2024
Q1 2024 -150 +9.93 +6.2% Mar 31, 2024
Q4 2023 -144 +23 +13.7% Dec 31, 2023
Q3 2023 -147 +36.5 +19.9% Sep 30, 2023
Q2 2023 -149 +44.7 +23.1% Jun 30, 2023
Q1 2023 -160 +57.3 +26.3% Mar 31, 2023
Q4 2022 -167 +92.1 +35.5% Dec 31, 2022
Q3 2022 -183 +149 +44.8% Sep 30, 2022
Q2 2022 -194 +462 +70.5% Jun 30, 2022
Q1 2022 -218 -3.72K -106% Mar 31, 2022
Q4 2021 -259 -522 -199% Dec 31, 2021
Q3 2021 -332 -483 -320% Sep 30, 2021
Q2 2021 -656 -747 -816% Jun 30, 2021
Q1 2021 3.5K Mar 31, 2021
Q4 2020 263 Dec 31, 2020
Q3 2020 151 Sep 30, 2020
Q2 2020 91.6 Jun 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.